GlassScriptPhysician profile
Dana L Brenner
NPI 1902850878
$3,644.05
in general payments reported to CMS, 2019-2025
22 companies · $960 in 2025
The $960 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $126 · 2021: $487 · 2022: $536 · 2023: $671 · 2024: $362 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.10 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $517.41 | 2022-2025 | Bijuva |
| Astellas Pharma US INC | $460.60 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $176.16 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $166.90 | 2021-2022 | |
| Lupin INC. | $162.88 | 2019-2020 | |
| Coopersurgical, INC. | $125.26 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Amgen INC. | $118.39 | 2022 | |
| Millicent US INC | $118.20 | 2024-2025 | Femlyv, Intrarosa |
| Biogen, INC. | $106.97 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $96.55 | 2023-2025 | Myfembree, Gemtesa |
| Shield Therapeutics INC | $48.89 | 2025 | |
| Evofem Biosciences, INC. | $41.48 | 2021-2023 | Phexxi |
| Meditrina | $23.70 | 2025 | |
| Hologic Sales and Service, LLC | $22.00 | 2023 | Thinprep 2000 Processor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2019 | |
| Scynexis, INC. | $18.74 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.48 | 2019 | |
| Trevena, INC. | $16.70 | 2021 | |
| Avion Pharmaceuticals | $16.29 | 2021 | |
| Allergan, INC. | $16.09 | 2019 | |
| Therapeuticsmd, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.